Application of Fragment-Based Drug Discovery against DNA GyraseB

被引：14

作者：

Chen, Guo-Ying ^{[1
]}

Ng, Fui Mee ^{[1
]}

Tan, Yih Wan ^{[1
]}

Poulsen, Anders ^{[1
]}

Seetoh, Weiguang ^{[1
]}

Lin, Grace ^{[1
]}

Kang, CongBao ^{[1
]}

Then, Siew Wen ^{[1
]}

Ahmad, Nur Huda ^{[1
]}

Wong, Ying Lei ^{[1
]}

Ng, Hui Qi ^{[1
]}

Chia, C. S. Brian ^{[1
]}

Lau, Qiu Ying ^{[1
]}

Hill, Jeffrey ^{[1
]}

Hung, Alvin W. ^{[1
]}

Keller, Thomas H. ^{[1
]}

机构：

[1] ASTAR, Ctr Expt Therapeut, Singapore 138667, Singapore

来源：

CHEMPLUSCHEM | 2015年 / 80卷 / 08期

关键词：

antibiotics; drug design; drug discovery; inhibitors; ligand effects; MYCOBACTERIUM-TUBERCULOSIS; ANTIBACTERIAL AGENTS; TOPOISOMERASE-IV; B PROTEIN; INHIBITORS; OPTIMIZATION; POTENT; HIT; RESISTANCE; DESIGN;

D O I：

10.1002/cplu.201500197

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Bacterial resistance to antibiotics remains a serious threat to global health. The gyraseB enzyme is a well-validated target for developing antibacterial drugs. Despite being an attractive target for antibiotic development, there are currently no gyraseB inhibitory drugs on the market. A fragment screen using 1,800compounds identified 14fragments that bind to Escherichia coli (E.coli) gyraseB. The detailed characterization of binding is described for all 14fragments. With the aid of X-ray crystallography, modifications on a low-affinity fragment (K-D=253M, IC50=634M) has led to the development of a new class of potent phenyl aminopyrazole inhibitors against E.coli gyraseB (IC50=160nM). The study presented here combines the use of a set of biophysical techniques including differential scanning fluorimetry, nuclear magnetic resonance, isothermal titration calorimetry, and X-ray crystallography to methodically identify, quantify, and optimize fragments into new chemical leads.

引用

页码：1250 / 1254

页数：5

共 50 条

[21] Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors
Svensson, Fredrik
Bender, Andreas
Bailey, David
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (04) : 1415 - 1424
[22] Ligand efficiency and fragment-based drug discovery
Bembenek, Scott D.
Tounge, Brett A.
Reynolds, Chades H.
DRUG DISCOVERY TODAY, 2009, 14 (5-6) : 278 - 283
[23] Fragment-based drug discovery through tethering
Erlanson, DA
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2763 - U2763
[24] What is the future for fragment-based drug discovery?
Keseru, Gyorgy M.
Hann, Michael M.
FUTURE MEDICINAL CHEMISTRY, 2017, 9 (13) : 1457 - 1460
[25] Advances in fragment-based drug discovery platforms
Orita, Masaya
Warizaya, Masaichi
Amano, Yasushi
Ohno, Kazuki
Niimi, Tatsuya
EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (11) : 1125 - 1144
[26] NMR Screening in the Fragment-based Drug Discovery
Hanzawa, Hiroyuki
Takizawa, Takeshi
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2010, 130 (03): : 325 - 333
[27] What makes a good fragment in fragment-based drug discovery?
Konteatis, Zenon
EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (07) : 723 - 726
[28] Fragment-Based Lead Discovery Strategies in Antimicrobial Drug Discovery
Konaklieva, Monika I.
Plotkin, Balbina J.
ANTIBIOTICS-BASEL, 2023, 12 (02):
[29] Fragment-Based Drug Discovery and Molecular Docking in Drug Design
Wang, Tao
Wu, Mian-Bin
Chen, Zheng-Jie
Chen, Hua
Lin, Jian-Ping
Yang, Li-Rong
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2015, 16 (01) : 11 - 25
[30] Fragment-based drug discovery using rational design
Jhoti, H.
SPARKING SIGNALS: KINASES AS MOLECULAR SIGNAL TRANSDUCERS AND PHARMACOLOGICAL DRUG TARGETS IN INFLAMMATION, 2008, 3 : 169 - 185

← 1 2 3 4 5 →